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Abstract Ischaemic cardiomyopathy is an important cardio-
vascular condition that has differing pathophysiological
substrates and clinical manifestations. Contemporary
management involves the administration of heart failure
pharmacotherapy and device therapy where indicated,
which has good prognostic data to support it. Whilst
the role of revascularisation is clear in those patients
presenting with an acute coronary syndrome or angina,
the role in those patients presenting either incidentally,
with predominant heart failure symptoms, or in those
presenting with acute heart failure with an associated
elevated troponin is less well defined and lacks randomised
outcome data to support its adoption. The aim of this review is
therefore to discuss the challenges in the diagnosis of ischae-
mic cardiomyopathy with a review of the existing imaging
modalities that can facilitate, and to revisit the variety of clin-
ical presentations that can occur, with particular emphasis on
the contemporary role of revascularisation in these cohorts of
patients.
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Introduction
Heart failure secondary to coronary artery disease, also known
as ischaemic cardiomyopathy (ICM), is an important cardio-
vascular condition that has a significant impact on both mor-
bidity and mortality [1, 2] that is managed across different
disciplines within the field of cardiology. ICM is increasing
in incidence [3] due to technological advancements in inter-
ventional and pharmacotherapy for acute myocardial infarc-
tion with overall improved survival, with a resultant increase
in the development of persistent left ventricular systolic
dysfunction (LVSD) in a subset of patients. It is important to
note that ICM rather than being a single entity represents a
spectrum of differing pathophysiological processes and clini-
cal manifestations. Clinically, patients can present with stable
angina, acute coronary syndromes and heart failure (with a
varying spectrum of severity) and can even present inciden-
tally without overt symptoms. The underlying pathophysiolo-
gy is more complex, andmultiple mechanisms can exist in one
patient. These include myocardial stunning, hibernation and
scar, leading to increased left ventricular volumes (with
irreversible remodelling) and varying degrees of regional or
global hypocontractility.
Evidence-based heart failure pharmacotherapy and device
therapy have been the mainstay of treatment for patients with
ICM across these differing pathophysiological and clinical
substrates, with good prognostic data to support it [4–7].
Whilst the role of revascularisation is well defined and recom-
mended in patients with an acute coronary syndrome (ACS)
and significant angina in several international guidelines [8,
9–11], this is less clear in those patients with predominant
heart failure symptoms or those who are asymptomatic. The
potential theoretical benefits of revascularisation are often
weighed up against its potential risks, particularly in those
patients where the evidence base is less well established.
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This has been further debated following the publication of the
Surgical Treatment for Ischaemic Heart Failure (STICH) trial,
which looked at the role of surgical revascularisation in ICM
and did not meet its primary outcome of all-cause mortality
[12••]. These results have led to a lack of clear consensus on
how these patients should be managed with regards to
revascularisation. The aim is therefore to review the issues
surrounding the diagnosis of ICM and its varying clinical
spectrum, and the role of revascularisation in the management
of the subset of patients who do not have angina as their
predominant symptom or who have not presented with an
acute myocardial infarction.
The Diagnostic Conundrum
ICM classically has been considered as a syndrome of heart
failure that is secondary to coronary artery disease. The term
cardiomyopathy, however, can be misleading and is often
contested by heart failure physicians, as cardiomyopathy re-
lates more to a primary myopathic process. It is important to
distinguish ICM from other causes of a cardiomyopathy, par-
ticularly for prognostic purposes as these patients have been
shown to have increased rates of mortality compared with
those with a non-ischaemic aetiology [13–15]. Felker et al.
sought to develop a prognostically powerful universal defini-
tion of ICM [16], through a retrospective observational study
of 1921 heart failure patients. Their results mirrored previous
studies, indicating a worse mortality with an ischaemic
aetiology; however, they also found that more extensive cor-
onary artery disease was independently associated with worse
survival. Interestingly, they also identified a group of patients
that had single-vessel coronary artery disease (excluding the
left main stem and proximal left anterior descending artery),
that using classical definitions would have been classified as
having ICM, yet they had similar outcomes to those patients
with no coronary artery disease. By reclassifying these pa-
tients into the non-ischaemic group, the investigators were
able to add power to their binary classification model for di-
agnosis. In a real-world setting, however, it is often left to the
judgement of the treating physician to decide whether the
coronary disease identified is out of proportion to the extent
of myocardial dysfunction. Techniques to further differentiate
the true ‘ischaemics’, with the ‘non-ischaemics’ are warrant-
ed, and data is needed on the clinical progression and man-
agement of those patients with mixed aetiology.
The Role of Invasive and Non-invasive Imaging
in the Diagnosis of ICM
Invasive coronary angiography remains the gold standard in
diagnosing coronary artery disease, and it is currently recom-
mended in patients with heart failure and anginal symptoms or
in those patients with demonstrable ischaemia and viability
but without angina [9, 11]. Even though to date there is no
trial data to support revascularisation in all patients with ICM,
the demonstration of coronary artery disease can be important
for both future management and prognostic purposes. The
presence of coronary disease will dictate important
evidence-based pharmacotherapy, including aspirin and
statins, which play an important role in preventing ischaemic
events, which if they occur can worsen LV function and have a
significant impact on morbidity and mortality. It is also impor-
tant to note that not only the presence but also the severity of
coronary artery disease is of prognostic significance and may
in the future influence the decision to revascularise or not if
the evidence base supports it. This was recently evaluated by a
substudy of the STICH trial, where the investigators studied
the impact of coronary anatomy and LV dimensions (three-
vessel coronary artery disease, ejection fraction below 28 %,
and end-systolic volume index above 79 ml/m2) on the effect
of coronary artery bypass grafting (CABG) in ICM [17••].
The investigators found that patients with more severe coro-
nary artery disease, worse remodelling and lower ejection
fraction received a significant mortality benefit from surgical
revascularisation. In those patients randomised to medical
therapy, there was significantly higher mortality in patients
with two or three of the prespecified prognostic factors
(p<0.001). However, invasive coronary angiography is not
without its risks and is therefore not recommended as a blan-
ket investigation for all patients with heart failure. CT angiog-
raphy may be a less invasive alternative in these patients, with
the added benefits of demonstrating regional wall thickness
and with certain imaging sequences detecting the presence or
absence of regional wall motion abnormalities.
Viability testing also plays an important role in the diag-
nostic work-up of ICM. Viability is a term that is used to
describe, on the basis of varying imaging features, regions of
the myocardium that have the potential to improve following
revascularisation. These regions of the myocardium, despite
being hypocontractile, demonstrate contractile reserve and
have preserved metabolic activity. Imaging plays an important
role in distinguishing areas of the myocardium that are scarred
and have undergone irreversible remodelling to those areas
that are in a reversible state of hypocontractility, as an adap-
tation to reduced myocardial blood flow. The different imag-
ing modalities that are available target different pathophysio-
logical mechanisms that identify areas that are viable. Whilst
echocardiography is the most widely available modality in
assessing viability, it is the least sensitive and specific due to
its low spatial resolution and the predominant dependence on
qualitative measures. Dobutamine stress echocardiography
(DSE) involves the administration of dobutamine at low, in-
termediate and high doses to assess the contractile reserve of
myocardial segments. A biphasic response has been shown to
be a hallmark of viability, with an initial improvement in
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contractility with low dose (demonstrating contractile re-
serve), with a subsequent deterioration in contractility at high
dose indicating ischaemia [18]. It is important to note that
whilst the presence of both viability and ischaemia have been
shown to be predictive of LV recovery following
revascularisation, the addition of ischaemia testing can aid
the diagnosis of ICM particularly in patients where the signif-
icance of epicardial disease is unclear. Nuclear modalities
such as positron emission tomography (PET) and single-
photon emission computed tomography (SPECT) provide in-
formation regarding myocardial perfusion and metabolism,
with PET being one of the most sensitive in identifying viable
myocardium (albeit at lower specificity than other modalities)
[19]. The main hallmark of viable myocardium is the presence
of perfusion metabolic mismatch (reduced perfusion with per-
sistent metabolic activity). Several studies have shown its clin-
ical utility in predicting recovery following revascularisation
[20–23], but its reduced availability and cost have limited its
widespread use. Cardiac magnetic resonance (CMR) imaging
is emerging as the one imaging modality that can provide
information on contractile reserve (low-dose dobutamine with
cine imaging), scar (late gadolinium enhancement, LGE) and
perfusion. LGE on CMR demonstrates areas of the myocardi-
um that consist of fibrosis. It has been shown that areas of
hypocontractility without scar are highly likely to recover
function following revascularisation; conversely, areas with
greater than 50 % of transmurality of LGE have a small
chance of recovery following revascularisation [24]. In pa-
tients with areas of scar less than 50 %, the addition of a
low-dose dobutamine run with cine imaging can highlight
those areas that have contractile reserve [25]. Despite decades
of observational studies demonstrating the relationship be-
tween the presence of viability using various non-invasive
imaging techniques and the improvement in mortality in pa-
tients revascularised [19], this has not been borne in
randomised trials [26, 27], suggesting that there are other fac-
tors at play other than viability that predict myocardial recov-
ery and a mortality reduction.
ICM Presenting as Acute Heart Failure
with an Elevated Troponin
Acute heart failure is a common and well-recognised compli-
cation of ischaemic cardiomyopathy. This can be in the con-
text of a de novo presentation with acute heart failure (in a
patient with no prior history) or acute decompensation in a
patient with chronic heart failure. Most of these patients will
be managed in a similar manner in most cardiology units
around the world, with a combination of intravenous diuretics,
nitroglycerin, morphine, non-invasive ventilation and, where
necessary, mechanical circulatory support. However, the chal-
lenge is in deciding which patients should be put forward for
angiography and acute revascularisation. The FINN-AKVA
study group sought to identify patient characteristics, varying
management strategies and survival in patients with acute
heart failure with and without an ACS [28]. They found that
patients with an ACS present more often with de novo heart
failure and had a more severe clinical manifestation of acute
heart failure. Short-term mortality was higher, and length of
hospital stay was longer in those patients with concurrent
ACS. It is therefore important to distinguish which patients
have a concurrent ACS and, therefore, should be put forward
for coronary angiography with subsequent revascularisation
in order to optimise their outcomes. Most patients presenting
with acute heart failure have an elevation of their troponin.
Aside from those presenting with acute chest pain or ECG
changes suggestive of myocardial ischaemia where a diagno-
sis of ACS is clear, those patients presenting with acute heart
failure and a mild to moderate rise in their troponin represent a
big management challenge. A recent study evaluated the value
of high-sensitivity troponin for identifying high-risk patients
with acute heart failure [29]. They found that 93 % of patients
enrolled had a high-sensitivity troponin above the normal val-
ue. Patients with worse LV dysfunction had higher troponin
values; however, on multivariate analysis, only the need for
inotropes predicted increased mortality. An analysis of the
RELAX-AHF study in a much larger cohort of patients found
that patients with a higher troponin value also had higher N-
terminal pro-brain natriuretic peptide levels, suggesting a
pathophysiological link between myocardial necrosis and
acute LV haemodynamic changes [30•]. They found that
higher baseline troponin values were associated with worse
overall outcomes. Another study by Latini et al. looked at
baseline troponin T levels in the Valsartan in Heart Failure
Trial (Val-HeFT) population, which consisted of a group of
stable heart failure patients. They found that troponin T was
detected using the high-sensitivity assay in 92 % of the pa-
tients enrolled. They found that patients with elevated tropo-
nin T concentrations (with the standard assay) or elevated
concentrations above 0.012 ng/mL using the high-sensitivity
assay were the greatest predictor for mortality and heart failure
hospitalisation [31]. Early revascularisation has been shown to
reduce mortality in those patients presenting with elevated
troponin levels [32], but the level of troponin at which this
benefit becomes apparent has yet to be elucidated. The release
of brain natriuretic peptide during an acute myocardial infarc-
tion has also been shown to be predictive of outcome [33], but
like troponin, its impact on guiding management has not been
tested in a randomised fashion.
When faced with a patient presenting with acute heart fail-
ure in the context of ICM, a decision about whether or not to
take the patient to the catheter laboratory should be made
early. Patients with either moderate or high levels of troponin
should be considered for angiography. Once coronary anato-
my is delineated, a Heart Team approach should be adopted,
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with the addition of further viability studies if required, to
decide whether revascularisation should be undertaken and
through which means. This should be considered carefully,
as these patients who have potentially the most to gain are
also at the highest risk of events during revascularisation
[34, 35]. In those patients with only minor elevations of tro-
ponin levels, other factors such as clinical presentation, renal
function, baseline troponin levels if known and electrocardio-
graphic features should be considered, alongside viability
testing.
ICM Presenting with Predominant Heart Failure
Symptoms
Despite decades of observational data showing a benefit with
revascularisation in patients with LVSD, particularly in those
with myocardial viability [19], there is no randomised trial
data to date that supports revascularisation in ICM for
prognosis. As a result, there are conflicting guidelines
on how these patients should be managed. The search
for hibernating myocardium (through viability testing
prior to revascularisation) has been the main clinical
and research focus in patients with ICM for many years.
Rahimtoola was one of the first to use the term hiber-
nation to describe a hypocontractile myocardium that is
in a down-regulated state as a result of processes occur-
ring at both the molecular and cell levels that improves
contractility following revascularisation [36]. This inter-
est in ICM and hibernation stemmed from the publica-
tion of the landmark surgical revascularisation studies,
but translation of this data to current practice is limited
by the selection bias inherent in most observational
studies, out-dated pharmacotherapy for heart failure used
and the fact that most patients undergoing revascularisation of
ICM had predominant anginal symptoms [37–39].
Evidence for Revascularisation
There is a large body of observational data that suggests a
mortality benefit with revascularisation in patients with
ICM. A meta-analysis performed by Allman et al. included
24 observational studies that assessed viability with a
variety of different imaging modalities [19]. A total of
3088 patients were included. When groups were stratified
according to those revascularised and those that were not,
there was a significant difference in mortality, with a much
lower mortality rate observed in those revascularised. There
was also a significant improvement in mortality in those
treated with revascularisation that had significant viability.
However, observational data is well known to be inherent to
many biases, particularly selection, which substantially
limits what can be concluded from the results.
The only two published randomised trials to date were
neutral in terms of their primary outcomes. The HEART-UK
trial was a multi-centre RCT that sought to answer the ques-
tion whether a strategy of invasive coronary angiography and
where suitable, revascularisation improved mortality in pa-
tients with demonstrable viability [40]. Unfortunately, this tri-
al was terminated early due to slow recruitment and hence was
underpowered to demonstrate any mortality differences. It
was also noted that a large proportion of patients did not un-
dergo their assigned intervention. The STICH trial [12••],
which is the largest completed trial to date that assessed
the impact of surgical revascularisation on clinical out-
comes in ICM, did not demonstrate an overall mortality
benefit with revascularisation. One thousand two hun-
dred twelve patients with an ejection fraction of less
than 35 % and coronary artery disease were randomly
assigned to undergo CABG alongside optimal medical
therapy (OMT) or OMT alone. Forty-one per cent of
patients in the OMT group reached the primary end
point of all-cause mortality, compared with 36 % of
patients in the CABG group (p = 0.12). There were
some signals of benefit seen in the secondary endpoints,
with a trend towards a reduction in cardiovascular cause
of death in the CABG group (p= 0.05). When the mode
of death was investigated, CABG was found to signifi-
cantly reduce sudden death and fatal pump failure
deaths (hazard ratios 0.73 and 0.64, respectively) [41].
There was also a significant reduction in deaths due to
myocardial infarctions. These effects were principally
seen late following CABG; in the first 30 days, there
was excess mortality in the surgical group. It is important to
note that approximately 10 % of patients assigned to each arm
crossed over into the other arm. In an as-treated analysis,
CABG did result in a significant reduction in the primary
end point [42].
Six hundred and one out of the 1212 enrolled into the
STICH trial underwent viability assessment. This was at
the discretion of the recruiting clinicians and was per-
formed in a non-randomised fashion. A subgroup analysis
of these patients was performed by Bonow et al., and a
total of 487 patients were found to have viable myocardi-
um as per prespecified definitions [27] on the basis of
SPECT and dobutamine stress echocardiography (DSE)
imaging. In these patients, revascularisation was not asso-
ciated with a reduction in all-cause mortality. One of the
main limitations of this substudy, apart from the fact that
viability testing was not mandated in the overall STICH
protocol, is that it lacked power to assess the impact of
viability, particularly as only 60 patients without viability
underwent CABG. The STICH investigators have
attempted to find other factors that could predict benefit
of revascularisation. A subgroup analysis of patients with
angina in the STICH trial was performed, and no
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association between the presence of angina and increased
survival benefit from surgical revascularisation was found
in an intention-to-treat analysis [43]. This is in contrast to
previous studies looking at the impact of symptoms on
prognosis in ICM.
As with many other randomised trials that involve patients
who are difficult to enrol, more hypotheses have been gener-
ated and there were more questions asked than answers deliv-
ered. The results of the STICH trial certainly challenge the
long-held clinical dogma, although the latter are based on
observational studies which themselves have many limita-
tions. There is clearly a need to perform more robust
randomised studies that would refute or clarify the questions
left in the wake of the STICH trial. Until then, patients should
continue to be managed on an individual basis. Certainly, at
present, we do not have the evidence to mandate
revascularisation in all patients with ICM, neither do we have
evidence to mandate viability testing in all patients with ICM.
The multi-centre open-labelled REVascularisation for
Ischaemic Ventricular Dysfunction-British Cardiovascular
Intervention Society-2 (REVIVED-BCIS-2, NCT01920048)
trial [45] is currently recruiting patients in the UK, which will
investigate the effect of percutaneous coronary intervention in
patients with ICM and evidence of viability. The Alternative
Imaging Modalities in Ischaemic Heart Failure (AIMI-HF)
trial is also recruiting, which will compare the effect
of standard imaging modalities (single-photon emission
computed tomography) to advanced imaging modalities
(cardiac magnetic resonance imaging or positron emis-
sion tomography) on the composite clinical end point
of cardiac death, myocardial infarction, resuscitated car-
diac arrest and cardiac rehospitalisation [46]. The re-
sults of these and future randomised studies are eagerly
awaited.
At present, existing international guidelines recommend
revascularisation in patients with LV dysfunction with coronary
anatomy that is suitable for revascularisation for prognostic pur-
poses [8, 9, 11, 44]. The most recent European Society of
Cardiology (ESC) guidelines on myocardial revascularisation
recommend CABG in patients with LV systolic dysfunction
and left main stem disease with class I level evidence C [8].
PCI may be considered if anatomy is suitable in the presence
of viable myocardium and when surgery is not indicated (class
IIb level evidence C). Revascularisation in stable coronary artery
disease in patients with a LVEF less that 40 % is given class I
level evidence A for prognostic purposes. The 2013 American
Heart Association heart failure guidelines recommend that
CABG should be undertaken in patients with operable anatomy
and ICM, with class IIb level evidence B, irrespective of the
presence of viability [9]. These guidelines are based predomi-
nantly on the results of observational studies and the STICH
results, the latter of which did not meet its primary outcome.
Please see Table 1 for a summary of the current international
guidelines.
ICM in the Asymptomatic Patient
Little is known about the incidence and clinical course of
patients with asymptomatic ischaemic cardiomyopathy. Data
from heart failure trials and observational studies indicate that
this population is not insignificant and are at significant risk of
development of heart failure symptoms, heart failure
hospitalisation and mortality [47, 48]. These patients often
present incidentally following an abnormal ECG, often per-
formed for an unrelated reason. Whilst angiography is very
useful to identify the cause of LV dysfunction and aid further
pharmacotherapy to target coronary artery disease, the
Table 1 Summary of existing international guidelines on revascularisation in patients with LV systolic dysfunctionwith predominant heart failure symptoms
Society Guideline Year Recommendation Class Level
AHA CABG 2011 CABG to improve survival is reasonable in patients with mild to moderate LV
systolic function (EF 35–50 %) and significant (≥75 % diameter stenosis)
multi-vessel CAD or proximal LAD stenosis, where viable myocardium is present
in the region of intended revascularisation
IIa B
AHA CABG 2011 CABGmight be considered with the primary or sole intent of improving survival in
patients with stable IHD with severe systolic dysfunction whether or not viable
myocardium is present
IIb B
AHA Heart failure 2013 CABG should be considered in patients with ICM and operable coronary anatomy
whether or not viable myocardium is present
IIb B
ESC Heart failure 2012 CABG is recommended for patients with angina and significant left main stem
stenosis, who are otherwise suitable for surgery to reduce the risk of premature death
I C
ESC Heart failure 2012 PCI may be considered as an alternative to CABG in patients unsuitable for surgery IIb C
ESC Myocardial
revascularisation
2014 Revascularisation for prognosis in patients with 2- or 3-vessel coronary artery




2014 CABG is recommended in left main stem stenosis in patients with severe LV
dysfunction
I C
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decision to revascularise like in patients with predominant
heart failure symptoms is complex. As with all other presen-
tations of ICM, good heart failure therapy and consideration
of device therapy is mandated. In terms of the diagnostic and
management work-up, viability testing should be considered
alongside testing for ischaemia and a Heart Team approach
should be adopted. Panza et al. identified the patients
out of the STICH population that underwent either a
radionuclide stress test or a DSE [49], and sought to
assess the prognostic significance of stress-induced is-
chaemia. There was no difference in the mortality be-
tween patients with or without ischaemia (p = 0.657).
When the patients were stratified according to their
treatment, no interaction was observed between the treat-
ment effects and the presence or absence of ischaemia. This
suggests that the presence of ischaemia does not predict
which patients would benefit from revascularisation in
this cohort of patients. This is in contrast with many
previous studies indicating a survival benefit with
revascularisation in those patients with significant is-
chaemia; however, the majority of these studies did
not enrol patients with a reduced ejection fraction. A
large observational series by Hachamovitch et al. in a group
of patients undergoing stress-rest myocardial perfusion scin-
tigraphy found that although the magnitude of ischaemic
myocardium is associated with a survival benefit with
revascularisation, this was only seen in patients without a prior
myocardial infarction [50]. Until further studies are performed
in this particular cohort of patients, revascularisation should
not be recommended for all patients, and the main focus
should be on managing their LV dysfunction.
Conclusions
ICM provides a fascinating clinical conundrum, relating to the
vast spectrum of underlying pathophysiological states and
clinical manifestations. Not only is the diagnosis a challenge,
but also the appropriate treatment especially with respect to
revascularisation is not fully known. Whilst the main-
stay of evidence-based treatment of ICM should focus
on pharmacotherapy for treating coronary artery disease
and heart failure and on device therapy where indicated,
the role of revascularisation needs to be elucidated fur-
ther, with the final aim of developing individualised
therapy that takes into account different factors that
may predict benefit from revascularisation. This includes
severity of LV dysfunction, severity of coronary artery
disease, evidence of viability and presence or absence of
ischaemia, which all need to be tested prospectively,
with the final aim of developing a model that can guide the
Heart Team in the management of this complex and high-risk
group of patients to ultimately improve outcomes.
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